

## PRESS RELEASE

---

16 February, 2021

### **Norwegian BioTec start-up Labrida AS enters extensive agreement with Swiss based Straumann Group, a global leader in dental care**

- **Labrida AS and Straumann Group agreed on an exclusive distribution agreement in key markets for Labrida BioClean™, a medical device class 2a for the maintenance of dental implant health**
- **Straumann Group has further strengthened its collaboration with Labrida by acquiring a minority stake in Labrida**

**Oslo, Norway, 16 February 2021:** Labrida AS and Straumann Group have entered into an agreement providing Straumann exclusive distribution rights in key markets for Labrida BioClean™ - a professional brush for managing long-term maintenance of implants. In 2021, Labrida and Straumann wish to expand the distribution agreement to more countries, mainly in Asia Pacific and emerging markets. Furthermore, Straumann Group has acquired a minority stake in Labrida and obtained option rights to increase its shareholding in the future. This allows Labrida to further invest into research and development as well as to scale-up production.

“The agreement with Straumann is a milestone for Labrida. Being a biotec start-up, with a product we believe in, we have an ambition to make our innovative solution accessible for dentists globally. With Straumann we found a powerful partner with a global distribution reach which is key. We are therefore proud to announce such an extensive agreement with one of the true benchmarks of the industry” says Tore Heldrup Rasmussen, Chairman of the Board of Labrida.

Labrida has developed, registered, and is marketing the Labrida BioClean™ brush for professional use, helping to significantly reduce inflammation, documented both in cases of peri-implant mucositis and mild peri-implantitis. The brush is made of the marine based substance chitosan, a biomaterial used for implant supportive care. A study performed by SINTEF, a Norwegian research institution, showed that Labrida BioClean® further helps to reduce the release of aerosols compared to traditional treatments, providing an additional option for dentist to meet newly imposed measurements for dental clinics due to COVID-19.

“The new partnership is truly a win-win for both companies. With the innovative professional brush for managing implant health, we will be able to offer dentists worldwide an additional solution for the maintenance of implants. Implant health is important to avoid inflammations or other complications in the long-term. The collaboration with Labrida allows us to extend our portfolio in implant health and to offer additional solutions for managing peri-implant diseases.”, says Holger Haderer, Head of Marketing & Education at Straumann Group.

Labrida BioClean™ is an alternative to existing treatments for the maintenance of dental implants. The implant health market is estimated to be about 70 million individuals worldwide, each patient typically needing 2-4 treatments per year. Labrida BioClean™ is also approved for periodontitis, a gums inflammation. This market is estimated to about 450 million individuals worldwide, and as such considered to be the world's 6<sup>th</sup> largest disease by incidence.

“We were hit hard by covid-19, as dental practises all around the globe were shut down overnight. Nonetheless, we have used this downtime productively and with the tireless support of our entire team, Innovation Norway, and of course the team at Straumann, we are now heading into 2021 with high hopes and expectations for strong commercial progress”, says Arvid Lindberg CEO of Labrida.

The agreement was mutually signed on December 18<sup>th</sup> 2020, and product launches throughout a vast number of European countries has already been either initiated or planned for 2021.

*About Labrida:*

*Labrida AS, is a Norwegian biotec company established in 2012. Labrida is developing and marketing a marine based dental medical device. Labrida BioClean® is a CE-marked, patented chitosan brush used by clinicians for maintenance of dental implants and/or teeth. Labrida BioClean® is sold to dental clinics in several markets in Europe. Through a milestone distribution agreement and partnership with Straumann, Labrida expects to face substantial growth in distribution and sales of its Labrida BioClean® brush going forward. Labrida is a privately held company with 39 shareholders and holds its headquarter in Oslo, Norway.*

*About Straumann:*

*The Straumann Group (SIX: STMN) is a global leader in tooth replacement and orthodontic solutions that restore smiles and confidence. It unites global and international brands that stand for excellence, innovation and quality in replacement, corrective and digital dentistry, including Anthogyr, ClearCorrect, Dental Wings, Medentika, Neodent, Straumann and other fully/partly owned companies and partners. In collaboration with leading clinics, institutes and universities, the Group researches, develops, manufactures and supplies dental implants, instruments, CAD/CAM prosthetics, biomaterials and digital solutions for use in tooth replacement and restoration or to prevent tooth loss. Headquartered in Basel, Switzerland, the Group currently employs approx. 7200 people worldwide and its products, solutions and services are available in more than 100 countries through a broad network of distribution subsidiaries and partners.*

**For Further information:**

**Labrida contact: Arvid Lindberg, CEO, +47 98 24 54 10  
or Tore Heldrup Rasmussen, Chairman of the Board, +47 90 77 47 77  
[www.labrida.no](http://www.labrida.no)**

**###**